StockNews.com Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

NASDAQ:GLMD opened at $7.33 on Monday. The company has a market cap of $36.98 million, a P/E ratio of -3.05 and a beta of 0.67. Galmed Pharmaceuticals has a 1 year low of $2.73 and a 1 year high of $23.80. The stock’s fifty day moving average price is $4.37 and its two-hundred day moving average price is $4.27.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.